US Stock Insider Trading | Aquestive disclosed 7 insider transactions on March 11

K-LinePoet · 2026-03-30T19:48:36+00:00

On March 11, 2026, Aquestive disclosed that executives conducted multiple insider transactions on March 10, selling a total of approximately 666,100 shares. The transactions involved several executives, at a unit price of $4.17.

K-LinePoet

2026-03-30 19:48:36

Abstract generation in progress

March 11, 2026, Aquestive (AQST) disclosed seven company insider trading transactions. Executive Barber Daniel sold 180,700 shares on March 10, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/US$	Total Amount/US$
March 11, 2026	Executive	Cioffi Melina	March 10, 2026	Sell	25,300	4.17	105,600
March 11, 2026	Executive	Jung Cassie	March 10, 2026	Sell	45,800	4.17	191,100
March 11, 2026	Executive	Boyd Peter E.	March 10, 2026	Sell	29,800	4.17	124,400
March 11, 2026	Executive	Barber Daniel	March 10, 2026	Sell	180,700	4.17	754,000
March 11, 2026	Executive	Korczynski Sherry	March 10, 2026	Sell	15,700	4.17	65,700
March 11, 2026	Executive	BRAENDER LORI J	March 10, 2026	Sell	40,100	4.17	167,300
March 11, 2026	Executive	TOTH A ERNEST JR	March 10, 2026	Sell	58,300	4.17	243,100
December 4, 2025	Executive	Cioffi Melina	December 2, 2025	Sell	2,083	5.93	12,400
October 17, 2025	Executive	Jung Cassie	October 15, 2025	Sell	67,600	7.01	473,700
October 17, 2025	Executive	Kraus Carl N	October 15, 2025	Sell	20,300	7.00	141,900

【Company Profile】

Aquestive Therapeutics, Inc. was founded in Delaware in January 2004. The company is a pharmaceutical enterprise that advances drugs through innovative delivery technologies. It focuses on developing alternatives to invasive standard therapies. It develops proprietary candidate drugs, including an adrenaline prodrug for anaphylactic shock, and it holds authorized commercialization products produced at its own facilities.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes